The SOUL study presented at the ACC conference in Chicago found that the oral form of the drug Ozempic, which mimics the human GLP-1 hormone, can reduce major cardiovascular events for high-risk type 2 diabetes patients. The study tracked patients for nearly five years and found a 14% reduction in cardiovascular events and a 26% drop in nonfatal heart attacks.
image sourced from original article at https://www.ynetnews.com/health_science/article/syqn8hip1lOriginal article source: https://www.ynetnews.com/health_science/article/syqn8hip1l
Source Id: 8613411478
